Chinese drugmakers showcase ADC data at ESMO, signaling biotech sector's global rise

Chinese biotech firms presented positive trial results, especially for antibody-drug conjugates, at the ESMO Congress, indicating growing international competitiveness. The data, though early-stage for some, underscores China's advancing innovation capabilities in oncology. This trend may reshape global pharma partnerships and competitive dynamics.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works